| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 4th, 2005 | 19 | Yes |
Popular Name: Chrysin Chrysin
Find On: PubMed — Wikipedia — Google
CAS Numbers: 480-40-0 , 480-40-1 , [480-40-0]
480-40-0; 5,7-Dihydroxyflavone; C10028; Chrysin
4H-1-benzopyran-4-one, 5,7-dihydroxy-2-phenyl-
5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one, 9CI;Chrysin;Chrysinic acid;Ois 3
5,7-Dihydroxy-2-phenyl-4H-chromen-4-one
5,7-Dihydroxy-2-phenyl-chromen-4-one
5,7-Dihydroxyflavone [480-40-0]; (Chrysin)
5,7-Dihydroxyflavone [480-40-0]; (Chrysin; 5,7,-dihydroxy-2-phenyl-4h-1-benzopyran-4-one)
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 2.94 | 3.96 | -11.62 | 2 | 4 | 0 | 71 | 254.241 | 1 | ↓ |
| Hi High (pH 8-9.5) | 2.94 | 4.94 | -56.85 | 1 | 4 | -1 | 73 | 253.233 | 1 | ↓ |
| Mid Mid (pH 6-8) | 3.20 | 4.26 | -45.71 | 1 | 4 | -1 | 73 | 253.233 | 1 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| biological_source | Isol. from Ulmus sieboldiana, Flourensia resinosa, Oroxylum indicum (bark), Pinus and Scutellaria spp. and others | ZereneX Building Blocks |
| Mp [°C] | 284 - 290 | Acros Organics |
| MP | 284-286o C | Indofine |
| Melting_Point | 284-289? | Alfa-Aesar |
| Melting_Point | 284-289° | Alfa-Aesar |
| M.P. | 285-286 C | Indofine |
| Purity | 99% | APIChem |
| Target | Cell division control protein 2 homolog(P06493)&Urokinase-type plasminogen activator(P00749)&Matrix metalloproteinase-9(P14780)&Sodium/potassium-transporting ATPase subunit gamma(P54710)&Alpha- and gamma-adaptin-binding protein p34(Q6PD74)&G2/mitotic-spec | Herbal Ingredients Targets |
| Therapy | diuretic | SMDC MicroSource |
| Warnings | IRRITANT | Matrix Scientific |
| mechanism | Lipid peroxidation inhibitor in rat liver microsomes | IBScreen Bioactives |
| Target | Others | Selleck Chemicals |
| S phrase | S24/25: Avoid contact with skin and eyes. | Acros Organics |
| biological_use | Shows antifungal activity | IBScreen Bioactives |
| SOLUBILITY | Soluble in 50 mg/ml Pyridine | Indofine |
| UniProt Database Links | SOT5_ARATH; UBGAT_SCUBA | ChEBI |
| APPEARANCE | Yellow-tan powder | Indofine |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| ABCG2-1-E | ATP-binding Cassette Sub-family G Member 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 2600 | 0.41 | Binding ≤ 10μM |
| ALDR-1-E | Aldose Reductase (cluster #1 Of 5), Eukaryotic | Eukaryotes | 7790 | 0.38 | Binding ≤ 10μM |
| AOFA-4-E | Monoamine Oxidase A (cluster #4 Of 8), Eukaryotic | Eukaryotes | 1600 | 0.43 | Binding ≤ 10μM |
| AOFB-4-E | Monoamine Oxidase B (cluster #4 Of 8), Eukaryotic | Eukaryotes | 1600 | 0.43 | Binding ≤ 10μM |
| CBR1-1-E | Carbonyl Reductase [NADPH] 1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 670 | 0.45 | Binding ≤ 10μM |
| CCNB1-1-E | G2/mitotic-specific Cyclin B1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 6200 | 0.38 | Binding ≤ 10μM |
| CCNB2-1-E | G2/mitotic-specific Cyclin B2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 6200 | 0.38 | Binding ≤ 10μM |
| CCNB3-1-E | G2/mitotic-specific Cyclin B3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 6200 | 0.38 | Binding ≤ 10μM |
| CDK1-1-E | Cyclin-dependent Kinase 1 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 6200 | 0.38 | Binding ≤ 10μM |
| CDK6-1-E | Cyclin-dependent Kinase 6 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 6000 | 0.38 | Binding ≤ 10μM |
| CP19A-3-E | Cytochrome P450 19A1 (cluster #3 Of 3), Eukaryotic | Eukaryotes | 2600 | 0.41 | Binding ≤ 10μM |
| CP1B1-1-E | Cytochrome P450 1B1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 24 | 0.56 | Binding ≤ 10μM |
| GBRA1-1-E | GABA Receptor Alpha-1 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.41 | Binding ≤ 10μM |
| GBRA2-1-E | GABA Receptor Alpha-2 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.41 | Binding ≤ 10μM |
| GBRA3-1-E | GABA Receptor Alpha-3 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.41 | Binding ≤ 10μM |
| GBRA4-1-E | GABA Receptor Alpha-4 Subunit (cluster #1 Of 7), Eukaryotic | Eukaryotes | 3020 | 0.41 | Binding ≤ 10μM |
| GBRA5-1-E | GABA Receptor Alpha-5 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.41 | Binding ≤ 10μM |
| GBRA6-6-E | GABA Receptor Alpha-6 Subunit (cluster #6 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.41 | Binding ≤ 10μM |
| GSK3A-2-E | Glycogen Synthase Kinase-3 Alpha (cluster #2 Of 3), Eukaryotic | Eukaryotes | 7200 | 0.38 | Binding ≤ 10μM |
| GSK3B-7-E | Glycogen Synthase Kinase-3 Beta (cluster #7 Of 7), Eukaryotic | Eukaryotes | 7200 | 0.38 | Binding ≤ 10μM |
| Q965D6-1-E | 3-oxoacyl-acyl-carrier Protein Reductase (cluster #1 Of 2), Eukaryotic | Eukaryotes | 10000 | 0.37 | Binding ≤ 10μM |
| XDH-2-E | Xanthine Dehydrogenase (cluster #2 Of 2), Eukaryotic | Eukaryotes | 840 | 0.45 | Binding ≤ 10μM |
| CP1A1-1-E | Cytochrome P450 1A1 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 42 | 0.54 | ADME/T ≤ 10μM |
| CP1A2-1-E | Cytochrome P450 1A2 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 84 | 0.52 | ADME/T ≤ 10μM |
| CP1B1-1-E | Cytochrome P450 1B1 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 16 | 0.57 | ADME/T ≤ 10μM |
| CP2C9-1-E | Cytochrome P450 2C9 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 5225 | 0.39 | ADME/T ≤ 10μM |
| Z104294-2-O | Cyclin-dependent Kinase 5/CDK5 Activator 1 (cluster #2 Of 2), Other | Other | 3100 | 0.41 | Binding ≤ 10μM |
| Z104301-4-O | GABA-A Receptor; Anion Channel (cluster #4 Of 8), Other | Other | 920 | 0.44 | Binding ≤ 10μM |
| Z50607-3-O | Human Immunodeficiency Virus 1 (cluster #3 Of 10), Other | Other | 5000 | 0.39 | Functional ≤ 10μM |
| Z80166-1-O | HT-29 (Colon Adenocarcinoma Cells) (cluster #1 Of 12), Other | Other | 3100 | 0.41 | Functional ≤ 10μM |
| Z80470-1-O | SGC-7901 (Gastric Carcinoma Cells) (cluster #1 Of 2), Other | Other | 5800 | 0.39 | Functional ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| CBR1_HUMAN | P16152 | Carbonyl Reductase [NADPH] 1, Human | 110 | 0.51 | Binding ≤ 1μM |
| CP19A_HUMAN | P11511 | Cytochrome P450 19A1, Human | 1 | 0.66 | Binding ≤ 1μM |
| CP1B1_HUMAN | Q16678 | Cytochrome P450 1B1, Human | 24 | 0.56 | Binding ≤ 1μM |
| Z104301 | Z104301 | GABA-A Receptor; Anion Channel | 920 | 0.44 | Binding ≤ 1μM |
| XDH_HUMAN | P47989 | Xanthine Dehydrogenase, Human | 840 | 0.45 | Binding ≤ 1μM |
| Q965D6_PLAFA | Q965D6 | 3-oxoacyl-acyl-carrier Protein Reductase, Plafa | 10000 | 0.37 | Binding ≤ 10μM |
| ALDR_BOVIN | P16116 | Aldose Reductase, Bovin | 7790 | 0.38 | Binding ≤ 10μM |
| ALDR_HUMAN | P15121 | Aldose Reductase, Human | 7780 | 0.38 | Binding ≤ 10μM |
| ABCG2_HUMAN | Q9UNQ0 | ATP-binding Cassette Sub-family G Member 2, Human | 1500 | 0.43 | Binding ≤ 10μM |
| CBR1_HUMAN | P16152 | Carbonyl Reductase [NADPH] 1, Human | 110 | 0.51 | Binding ≤ 10μM |
| CDK1_HUMAN | P06493 | Cyclin-dependent Kinase 1, Human | 6200 | 0.38 | Binding ≤ 10μM |
| Z104294 | Z104294 | Cyclin-dependent Kinase 5/CDK5 Activator 1 | 3100 | 0.41 | Binding ≤ 10μM |
| CDK6_HUMAN | Q00534 | Cyclin-dependent Kinase 6, Human | 6000 | 0.38 | Binding ≤ 10μM |
| CP19A_HUMAN | P11511 | Cytochrome P450 19A1, Human | 1 | 0.66 | Binding ≤ 10μM |
| CP1B1_HUMAN | Q16678 | Cytochrome P450 1B1, Human | 24 | 0.56 | Binding ≤ 10μM |
| CCNB1_HUMAN | P14635 | G2/mitotic-specific Cyclin B1, Human | 6200 | 0.38 | Binding ≤ 10μM |
| CCNB2_HUMAN | O95067 | G2/mitotic-specific Cyclin B2, Human | 6200 | 0.38 | Binding ≤ 10μM |
| CCNB3_HUMAN | Q8WWL7 | G2/mitotic-specific Cyclin B3, Human | 6200 | 0.38 | Binding ≤ 10μM |
| GBRA1_HUMAN | P14867 | GABA Receptor Alpha-1 Subunit, Human | 3019.95172 | 0.41 | Binding ≤ 10μM |
| GBRA2_HUMAN | P47869 | GABA Receptor Alpha-2 Subunit, Human | 3019.95172 | 0.41 | Binding ≤ 10μM |
| GBRA3_HUMAN | P34903 | GABA Receptor Alpha-3 Subunit, Human | 3019.95172 | 0.41 | Binding ≤ 10μM |
| GBRA4_HUMAN | P48169 | GABA Receptor Alpha-4 Subunit, Human | 3019.95172 | 0.41 | Binding ≤ 10μM |
| GBRA5_HUMAN | P31644 | GABA Receptor Alpha-5 Subunit, Human | 3019.95172 | 0.41 | Binding ≤ 10μM |
| GBRA6_HUMAN | Q16445 | GABA Receptor Alpha-6 Subunit, Human | 3019.95172 | 0.41 | Binding ≤ 10μM |
| Z104301 | Z104301 | GABA-A Receptor; Anion Channel | 920 | 0.44 | Binding ≤ 10μM |
| GSK3A_HUMAN | P49840 | Glycogen Synthase Kinase-3 Alpha, Human | 7200 | 0.38 | Binding ≤ 10μM |
| GSK3B_HUMAN | P49841 | Glycogen Synthase Kinase-3 Beta, Human | 7200 | 0.38 | Binding ≤ 10μM |
| AOFA_HUMAN | P21397 | Monoamine Oxidase A, Human | 1600 | 0.43 | Binding ≤ 10μM |
| AOFB_HUMAN | P27338 | Monoamine Oxidase B, Human | 1600 | 0.43 | Binding ≤ 10μM |
| XDH_HUMAN | P47989 | Xanthine Dehydrogenase, Human | 840 | 0.45 | Binding ≤ 10μM |
| Z80166 | Z80166 | HT-29 (Colon Adenocarcinoma Cells) | 3100 | 0.41 | Functional ≤ 10μM |
| Z50607 | Z50607 | Human Immunodeficiency Virus 1 | 5000 | 0.39 | Functional ≤ 10μM |
| Z80470 | Z80470 | SGC-7901 (Gastric Carcinoma Cells) | 5800 | 0.39 | Functional ≤ 10μM |
| CP1A1_HUMAN | P04798 | Cytochrome P450 1A1, Human | 153 | 0.50 | ADME/T ≤ 10μM |
| CP1A2_HUMAN | P05177 | Cytochrome P450 1A2, Human | 54 | 0.54 | ADME/T ≤ 10μM |
| CP1B1_HUMAN | Q16678 | Cytochrome P450 1B1, Human | 16 | 0.57 | ADME/T ≤ 10μM |
| CP2C9_HUMAN | P11712 | Cytochrome P450 2C9, Human | 5225 | 0.39 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Abacavir transmembrane transport | |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | |
| Aflatoxin activation and detoxification | |
| AKT phosphorylates targets in the cytosol | |
| APC truncation mutants have impaired AXIN binding | |
| APC/C:Cdc20 mediated degradation of Cyclin B | |
| Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 | |
| AXIN missense mutants destabilize the destruction complex | |
| Beta-catenin phosphorylation cascade | |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |
| Condensation of Prometaphase Chromosomes | |
| Condensation of Prophase Chromosomes | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| CRMPs in Sema3A signaling | |
| Cyclin A/B1 associated events during G2/M transition | |
| Cyclin B2 mediated events | |
| Cyclin D associated events in G1 | |
| CYP2E1 reactions | |
| Degradation of beta-catenin by the destruction complex | |
| Depolymerisation of the Nuclear Lamina | |
| disassembly of the destruction complex and recruitment of AXIN to the membrane | |
| E2F mediated regulation of DNA replication | |
| E2F-enabled inhibition of pre-replication complex formation | |
| Endogenous sterols | |
| Enzymatic degradation of dopamine by COMT | |
| Enzymatic degradation of Dopamine by monoamine oxidase | |
| ERK1 activation | |
| Estrogen biosynthesis | |
| G0 and Early G1 | |
| G1/S-Specific Transcription | |
| G2/M DNA replication checkpoint | |
| GABA A receptor activation | |
| Golgi Cisternae Pericentriolar Stack Reorganization | |
| Iron uptake and transport | |
| Ligand-gated ion channel transport | |
| Loss of Nlp from mitotic centrosomes | |
| Loss of proteins required for interphase microtubule organization from the ce | |
| MASTL Facilitates Mitotic Progression | |
| Metabolism of serotonin | |
| Methylation | |
| misspliced GSK3beta mutants stabilize beta-catenin | |
| Monoamines are oxidized to aldehydes by MAOA and MAOB, producing NH3 and H2O2 | |
| Norepinephrine Neurotransmitter Release Cycle | |
| Nuclear Pore Complex (NPC) Disassembly | |
| Oncogene Induced Senescence | |
| Oxidative Stress Induced Senescence | |
| Phosphorylation of Emi1 | |
| Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 com | |
| Phosphorylation of the APC/C | |
| Polo-like kinase mediated events | |
| PPARA activates gene expression | |
| Pregnenolone biosynthesis | |
| Purine catabolism | |
| Recruitment of mitotic centrosome proteins and complexes | |
| Recruitment of NuMA to mitotic centrosomes | |
| Regulation of APC/C activators between G1/S and early anaphase | |
| Regulation of HSF1-mediated heat shock response | |
| Regulation of PLK1 Activity at G2/M Transition | |
| Resolution of Sister Chromatid Cohesion | |
| S33 mutants of beta-catenin aren't phosphorylated | |
| S37 mutants of beta-catenin aren't phosphorylated | |
| S45 mutants of beta-catenin aren't phosphorylated | |
| Senescence-Associated Secretory Phenotype (SASP) | |
| Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) | |
| Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | |
| T41 mutants of beta-catenin aren't phosphorylated | |
| truncations of AMER1 destabilize the destruction complex | |
| XBP1(S) activates chaperone genes | |
| Xenobiotics |